Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer

Nivolumab for the treatment of advanced nonsmall cell lung cancer (NSCLC) evaluated in phase III trials showed 50% progression at first evaluation, but better overall survival (OS), suggesting regained efficacy of treatments given thereafter. We aimed to evaluate the efficacy of nivolumab and of nex...

Descripción completa

Detalles Bibliográficos
Autores principales: Costantini, Adrien, Corny, Jennifer, Fallet, Vincent, Renet, Sophie, Friard, Sylvie, Chouaid, Christos, Duchemann, Boris, Giroux-Leprieur, Etienne, Taillade, Laurent, Doucet, Ludovic, Nguenang, Marina, Jouveshomme, Stéphane, Wislez, Marie, Tredaniel, Jean, Cadranel, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909051/
https://www.ncbi.nlm.nih.gov/pubmed/29692997
http://dx.doi.org/10.1183/23120541.00120-2017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909051/
https://www.ncbi.nlm.nih.gov/pubmed/29692997
http://dx.doi.org/10.1183/23120541.00120-2017

Ejemplares similares